Moreover, for patients with HER2-overexpressing G/GEJ cancer who have not responded to first-line therapies, as well as those with advanced BTC, KN026 and zanidatamab (BSABs targeting HER2 domains ECD2 and ECD4) present promising therapeutic options. The gene discussed is ERBB2; the disease is cancer.